Oramed Pharmaceuticals (NASDAQ:ORMP) Lowered to “Hold” Rating by StockNews.com

StockNews.com cut shares of Oramed Pharmaceuticals (NASDAQ:ORMP) from a buy rating to a hold rating in a report published on Monday morning.

Separately, HC Wainwright reissued a “neutral” rating on shares of Oramed Pharmaceuticals in a report on Monday, September 9th.

Oramed Pharmaceuticals Price Performance

Shares of Oramed Pharmaceuticals stock opened at $2.32 on Monday. The business has a fifty day simple moving average of $2.38 and a two-hundred day simple moving average of $2.38. Oramed Pharmaceuticals has a 1 year low of $1.99 and a 1 year high of $3.67. The company has a market capitalization of $93.52 million, a price-to-earnings ratio of 4.55 and a beta of 1.77.

Oramed Pharmaceuticals (NASDAQ:ORMP) last posted its earnings results on Wednesday, August 14th. The biotechnology company reported $0.22 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.21. As a group, equities analysts anticipate that Oramed Pharmaceuticals will post 0.24 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Oramed Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of ORMP. Dimensional Fund Advisors LP raised its stake in Oramed Pharmaceuticals by 52.1% in the second quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company’s stock valued at $81,000 after purchasing an additional 10,774 shares in the last quarter. XTX Topco Ltd acquired a new position in Oramed Pharmaceuticals in the second quarter valued at about $40,000. Virtu Financial LLC acquired a new position in Oramed Pharmaceuticals in the first quarter valued at about $68,000. Renaissance Technologies LLC raised its stake in Oramed Pharmaceuticals by 89.0% in the second quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock valued at $593,000 after purchasing an additional 108,700 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in Oramed Pharmaceuticals in the third quarter valued at about $272,000. Institutional investors and hedge funds own 12.73% of the company’s stock.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.